No Data
No Data
Opus Genetics Announces 1-Yr Results From Adult Patients Treated In Ongoing Phase 1/2 Study Of Lead Gene Therapy Candidate OPGx-LCA5
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Opus Genetics Founder Mina Sooch Withdraws Proxy Fight, Criticizes Company Over 'Dilutive Financing and Governance Concerns'
Express News | Mina Sooch: To Exercise Rights as a Stockholder by Voting 'withhold' on Opus Genetics Board’s Nominees in Proposal 1 at AGM
Express News | Mina Sooch: Issued Open Letter to Opus Genetics' Stockholders